Abstract Number: L20 • 2019 ACR/ARP Annual Meeting
A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naïve Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks
Background/Purpose: Multiple biologic DMARDs (bDMARDs) are available for treatment of PsA, but there are few direct comparisons of their efficacy and safety. Furthermore, efficacy of…Abstract Number: 1010 • 2019 ACR/ARP Annual Meeting
IL-17A Induces Distinct Functional Differences Between Two Novel Mesenchymal Stem Cell Populations Identified at the Human Enthesis
Background/Purpose: Ankylosing spondylitis (AS) is associated with entheseal inflammation and new bone formation. Resident populations of lymphocytes have been identified at the enthesis that on…Abstract Number: 1553 • 2019 ACR/ARP Annual Meeting
Impact of Peripheral Swollen and Tender Joints at Baseline on Response to Treatment with Secukinumab in Ankylosing Spondylitis
Background/Purpose: AS is a chronic, inflammatory disease of the axial skeleton associated with pain, stiffness, disability, and reduced quality of life (QOL).1 AS is defined…
ACR Meeting Abstracts